M
MapLight Therapeutics
Biotech & Life Sciences · Redwood City, United States · Founded 2018 · IPO 2025
Precision neuroscience developing targeted therapies for serious brain disorders MoreLess
MapLightRx is a pioneering startup in the healthcare sector, specifically focusing on brain disorders such as Autism, Parkinson's, and Schizophrenia. The company is on a mission to revolutionize the current treatment landscape, which is characterized by limited options, moderate effectiveness, and significant side effects. MapLightRx aims to provide more targeted and effective treatments for patients, moving away from the traditional approach of using generalized therapeutics.
The company operates in the medical research and development market, serving patients suffering from brain disorders. Its business model revolves around the development of a unique discovery platform that combines advanced technologies to identify and target the individual circuits that malfunction in brain disorders. This platform is built on proprietary, patented innovations such as optogenetics, STARmap, and transcriptomics.
MapLightRx's revenue generation strategy is based on the development and commercialization of safe, effective therapeutics for brain disorders. The company has a strong pipeline of potential treatments, with two lead compounds already in clinical trials. These treatments show promise for multiple indications and disorders, including social deficits related to Autism and unwanted movements related to Parkinson's disease.
In summary, MapLightRx is a promising startup in the healthcare sector, leveraging cutting-edge technologies to develop targeted treatments for brain disorders. Its unique approach and strong pipeline of potential treatments position it well for future growth in the medical research and development market.
Keywords: Healthcare, Brain Disorders, Autism, Parkinson's, Schizophrenia, Medical Research, Development, Optogenetics, STARmap, Transcriptomics.
Talent graph
MapLight Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where MapLight Therapeutics has talent and traffic
team presence
across markets
Patent intelligence
$2M patent portfolio · 7 active families
Where MapLight Therapeutics concentrates vs peers
Each axis is a top-10 topic across MapLight Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about MapLight Therapeutics
An AI-synthesized read of the highest-engagement posts about MapLight Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MapLight Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.








